Priacin Indications/Uses

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate.
Patients at High Risk or Existing Coronary Heart Disease (CHD): In patients at high risk of coronary events because of existing CHD, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, Priacin is indicated to reduce the risk of total mortality by reducing CHD deaths; reduce the risk of nonfatal MI and stroke and reduce the need for coronary and noncoronary revascularization procedures.
In hypercholesterolemic patients with CHD, Priacin slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.
Patients with Hyperlipidemia: Adjunct to diet to reduce elevated total-C, LDL-C, TG and apo B and to increase HDL-C in patients with primary hypercholesterolemia including heterozygous familial hypercholesterolemia (Fredrickson type IIa) or combined (mixed) hyperlipidemia (Fredrickson type IIb), when response to diet and other nonpharmacological measures is inadequate. Priacin, therefore, lowers LDL-C/HDL-C and total-C/HDL-C ratios.
Adjunct to diet and other nondietary measures for the treatment of patients with homozygous familial hypercholesterolemia to reduce elevated total-C, LDL-C and apo B.